Evolution of light chain deposition disease over 8 years

Clinical Nephrology

Volumn 72, Issue 5, 2009, Pages 397-401

  Gerth, J ^a   Busch, M ^a   Ott, U ^a   Groene, H J ^b   Wolf, Gunter ^a  

^a FRIEDRICH SCHILLER UNIVERSITY JENA   (Germany)

^b GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

Author keywords

Light chain deposition disease; Myeloma; Renal insufficiency

Indexed keywords

HEMOGLOBIN A1C; IMMUNOGLOBULIN LAMBDA CHAIN; MELPHALAN; RAMIPRIL; VALSARTAN;

ADULT; ALBUMINURIA; ARTICLE; CASE REPORT; DRUG DOSE INCREASE; FEMALE; GLOMERULUS FILTRATION RATE; HEADACHE; HEMOGLOBIN BLOOD LEVEL; HUMAN; HYPERTENSION; IMMUNOGLOBULIN BLOOD LEVEL; IMMUNOGLOBULIN DEPOSITION; KIDNEY BIOPSY; KIDNEY FAILURE; LIGHT CHAIN DEPOSITION DISEASE; MICROCYTIC ANEMIA; MONOCLONAL IMMUNOGLOBULINEMIA; PLASMA CELL; PROTEINURIA; TREATMENT REFUSAL;

EID: 70350751312     PISSN: 03010430     EISSN: None     Source Type: Journal    
DOI: 10.5414/cnp72397     Document Type: Article

References (15)

1. Brockhurst I, Harris KPG, Chapman CS. Diagnosis and monitoring a case of light-chain deposition disease in the kidney using a new, sensitive immunoassay. Nephrol Dial Transplant. 2005; 20: 1251-1253.
2. Demeule B, Gurny R, Arvinte T. Where disease pathogenesis meets protein formulation: renal deposition of immunoglobulin aggregates. Eur J Pharmaceut Biopharmaceut. 2006; 62: 121-130.
3. Dispenzieri A, Kyle RA, Lacy MQ et al. Superior survival in primary systemic amyloidosis patients undergoing peripheral blood stem cell transplantation: a case control study. Blood 2004; 103: 3960-3963.
4. Firkin F, Hill PA, Dwyer K, Gock H. Reversal of dialysis-dependent renal failure in light-chain deposition disease by autologous peripheral blood stem cell transplantation. Am J Kidney Dis. 2004; 44: 551-555.
5. Gokden N, Barlogie B, Liapis H. Morphologic heterogeneity of renal light-chain deposition disease. Ultrastruct Pathol. 2008; 32: 17-24.
6. Jaccard A, Moreau P, Leblond V et al. High-dose melphalan versus melphalan plus dexamethasone for AL amyloidosis. N Engl J Med. 2007; 357: 1083-1093.
7. Keeling J, Herrera GA. An in vitro model of light chain deposition disease. Kidney In. 2009; (in press).
8. Komatsuda A, Wakui H, Ohtani H et al. Disappearance of nodular mesangial lesions in a patient with light chain nephropathy after long-term chemotherapy. Am J Kid Dis. 2000; 35: 1-5.
9. Lorenz EC, Gertz MA, Fervenza FC et al. Long-term outcome of autologous stem cell transplantation in light chain deposition disease. Nephrol Dial Transplant. 2008; 23: 2052-2057.
10. Masai R, Wakui H, Togashi M et al. Clinicopathological features and prognosis in immunoglobulin light and heavy chain deposition disease. Clin Nephrol. 2009; 71: 9-20
11. Pérez-Suárez G, Raya, JM, Alvárez A, Martín A, Alvárez-Arguelles H, Hernández-García M, Hernández D. Progressive renal failure as the first manifestation of monoclonal light chain deposition disease with multiple organ involvement. Clin Nephrol. 2009; 71: 314-318.
12. Pozzi C, D'Amico M, Fogazzi GB et al. Light chain deposition disease with renal involvement: clinical characteristics and prognostic factors. Am J Kidney Dis. 2003; 42: 1154-1163.
13. Randall RE, Williamson WC, Mullinax F, Tung M, Still WJ. Manifestations of systemic light chain deposition. Am J Med. 1976; 60: 293-299.
14. Ronco P, Plaisier E, Mougenot B, Aucouturier P. Immunoglobulin light (heavy)-chain deposition disease: from molecular medicine to pathophysiology-driven therapy. Clin J Am Soc Nephrol. 2006; 1: 1342-1350.
15. Salant DJ, Sachorawala V, D'Agati VD. A case of atypical light chain deposition disease- diagnosis and treatment. Clin J Am Soc Nephrol. 2007; 2: 858-867.